BCACP Hypertension and Dyslipidemia Therapy 3

Question 1

Which PCSK9 inhibitor is FDA-approved as a twice-yearly subcutaneous injection for LDL reduction?

Accepted Answer

Inclisiran

Answer

Evolocumab

Answer

Alirocumab

Answer

Bempedoic acid

Question 2

A patient with hypertension and gout flares is on hydrochlorothiazide. What is the most appropriate change?

Accepted Answer

Switch to losartan

Answer

Add allopurinol and continue HCTZ

Answer

Switch to chlorthalidone

Answer

Switch to furosemide

Question 3

Which lipid-lowering drug is most associated with flushing as a side effect and requires premedication with aspirin?

Accepted Answer

Niacin (nicotinic acid)

Answer

Fenofibrate

Answer

Ezetimibe

Answer

Colesevelam

Question 4

A 70-year-old patient is on simvastatin 40 mg and is newly started on amlodipine. What drug interaction concern exists?

Accepted Answer

Amlodipine inhibits CYP3A4 and increases simvastatin exposure

Answer

Amlodipine reduces simvastatin efficacy

Answer

No clinically significant interaction exists

Answer

Amlodipine displaces simvastatin from plasma proteins

Question 5

According to ACC/AHA guidelines, what is the LDL goal for a very high-risk ASCVD patient on maximally tolerated statin therapy?

Accepted Answer

<55 mg/dL

Answer

<100 mg/dL

Answer

<70 mg/dL

Answer

<40 mg/dL

Question 6

Which antihypertensive is the preferred choice in a patient with hypertension and heart failure with reduced ejection fraction (HFrEF)?

Accepted Answer

Carvedilol

Answer

Amlodipine

Answer

Diltiazem

Answer

Clonidine

Question 7

A patient with hypertension and bilateral renal artery stenosis is being considered for antihypertensive therapy. Which drug class should be AVOIDED?

Accepted Answer

ACE inhibitors

Answer

Calcium channel blockers

Answer

Alpha-blockers

Answer

Thiazide diuretics